UAE Pharmaceutical Manufacturing License Guide 2026: How to Set Up a Drug or Medicine Manufacturing Facility in UAE

Updated August 2026. The UAE has set one of the most ambitious pharmaceutical self-sufficiency targets in the Middle East: reduce medicine import dependency from 80% to 50% by 2031. That policy shift — backed by the UAE Health Security Strategy 2026–2031 — is opening a clear investment window for manufacturers willing to navigate the Ministry of Health and Prevention (MOH) licensing pathway. This guide covers every stage: company formation, GMP facility construction, MOH Manufacturing Authorization, product registration, and the economics of operating in UAE’s dedicated pharmaceutical zones. Whether you are evaluating a greenfield tablet plant or a sterile injectable facility, the process and numbers are laid out below.

UAE Pharmaceutical Market: Why Now

The UAE pharmaceutical market grew to over AED 18 billion in 2025, driven by a population of 10 million, medical tourism, and Gulf re-export trade. Yet roughly 80% of that demand is met by imports — a strategic vulnerability the government has moved to address through the UAE Health Security Strategy and parallel industrial policy channelled through KIZAD and Abu Dhabi’s Health Cluster.

Local manufacturing currently accounts for approximately AED 3 billion of output and is growing at 25% per year. The federal government’s incentive package — free zone licences, land subsidies, government offtake commitments, and fast-tracked MOH registration for domestically manufactured products — is designed to close the gap. Julphar (Ras Al Khaimah), Neopharma (Abu Dhabi), and Tabuk Pharma are the anchor manufacturers; the next generation of entrants is expected to focus on biosimilars, injectables, and complex generics. Planned pharmaceutical FDI announced for the 2024–2030 window exceeds AED 5 billion.

UAE Pharmaceutical Regulatory Framework

Three health authorities operate in parallel. Understanding which body handles what — and at which stage — is essential to planning a realistic timeline.

For a manufacturer, the MOH federal pathway is the primary track. The Manufacturing Authorization issued by MOH is recognised across all seven emirates and is the prerequisite for selling to any UAE health facility. DHA or DOH product registration is an additional step required to sell specifically in those emirates’ public health systems.

Drug applications use the ICH CTD (Common Technical Dossier) format — the same international submission format used in Europe, the US, and Singapore. This reduces duplication for manufacturers who already hold a European or US product licence. GMP compliance is assessed against ICH Q7 / UAE GMP standards, which align closely with EU GMP and WHO GMP guidelines.

Step-by-Step: UAE Pharmaceutical Manufacturing Authorization Process

The process from company formation to first commercial batch typically takes 3–5 years for a greenfield facility. The timeline compresses if the investor acquires or contracts with an existing GMP-certified site. Each step below is a formal milestone with a corresponding MOH or trade authority action.

Dosage Forms, GMP Classes and Indicative Capex

The MOH Manufacturing Authorization is granted per dosage form category and sterility class. A facility holding an MA for solid oral dosage forms cannot manufacture sterile injectables without a separate inspection and a separate MA scope extension. Capex varies by two orders of magnitude depending on the dosage form chosen.

Capital Cost Breakdown: Solid Oral Dosage Facility (Year 1)

The solid oral dosage category is the most accessible entry point for a new pharmaceutical manufacturer in UAE. The table below details realistic Year 1 costs for a 5,000 sqm GMP-certified facility located in KIZAD, dimensioned to manufacture approximately 500 million tablets per year across 10 registered products.

KIZAD Pharmaceutical Zone: Infrastructure and Incentives

KIZAD (Khalifa Industrial Zone Abu Dhabi) is UAE’s purpose-built heavy and pharmaceutical industrial zone adjacent to Khalifa Port — the UAE’s largest container port and a direct gateway to GCC pharmaceutical exports. For pharmaceutical manufacturers, KIZAD offers a combination of pre-installed GMP infrastructure and free zone fiscal benefits that significantly de-risk the setup phase.

For manufacturers targeting GCC export markets, KIZAD’s position adjacent to Khalifa Port provides a direct logistics pathway to Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman — all markets where UAE-manufactured, Halal-certified pharmaceutical products hold a credibility premium over products from non-GCC origin countries.

Revenue Model and Market Opportunity

The economics of UAE pharmaceutical manufacturing are compelling when government procurement channels are taken into account. MOH, DHA, and HAAD collectively purchase over AED 2 billion per year from local manufacturers — and the government’s import substitution strategy explicitly prioritises locally sourced medicines in procurement tenders.

Frequently Asked Questions

How do I obtain a MOH Manufacturing Authorization for drugs in the UAE?

The MOH Manufacturing Authorization (MA) is a federal licence issued by the UAE Ministry of Health and Prevention (MOH) that permits a specific pharmaceutical facility to manufacture defined dosage forms. The process begins after company formation (DED or free zone licence with pharmaceutical manufacturing activity) and requires constructing a GMP-compliant facility. MOH inspectors conduct 2–3 pre-authorization visits to verify that the facility, equipment, quality systems, and documentation meet UAE GMP / ICH Q7 standards. Once inspections are passed, MOH issues the MA scoped to the approved dosage form categories and sterility class — for example, non-sterile solid oral dosage forms, or sterile injectables. The MA is not a product registration: each drug product (SKU) still requires a separate CTD-format dossier submission to the MOH drug register, with fees of AED 15,000–50,000 per product. Post-authorization, manufacturers are subject to annual surveillance inspections and must renew the MA every 3 years.

What are the GMP facility requirements for pharmaceutical manufacturing in the UAE?

All pharmaceutical manufacturing facilities in the UAE must comply with UAE GMP standards, which align with ICH Q7 and WHO GMP guidelines. The core requirements include: cleanroom classification appropriate to the dosage form (ISO Class 5 aseptic zones for sterile injectables; controlled classified areas for tablets and liquids); HVAC systems with validated pressure differentials, temperature, humidity, and particle count monitoring; purified water (PW) or water-for-injection (WFI) systems for sterile products; validated manufacturing and QC equipment documented through IQ/OQ/PQ qualification protocols; a quality management system (QMS) covering standard operating procedures (SOPs), batch records, change control, deviation management, and out-of-specification (OOS) investigation processes; a QC laboratory equipped for identity, assay, dissolution, microbiology, and stability testing; and trained personnel with documented qualifications in pharmaceutical manufacturing, quality assurance, and regulatory affairs. MOH inspectors assess all these elements before issuing a Manufacturing Authorization, and verify annually during surveillance inspections.

How much does it cost to set up a pharmaceutical factory in the UAE?

The total investment depends primarily on the dosage form category. A solid oral dosage facility (tablets and capsules) in KIZAD — a realistic entry-level investment for a generic manufacturer — requires AED 55.5 million to AED 116 million in Year 1, covering land lease and building (AED 10M–25M), GMP fit-out of cleanrooms, HVAC, and water systems (AED 20M–40M), manufacturing equipment including tablet presses, coaters, and packaging lines (AED 15M–30M), a QC laboratory with analytical instruments (AED 5M–10M), regulatory fees and product registration dossiers for 10 products (AED 500K–1M), and Year 1 staff including production, QA/QC, regulatory, and engineering teams (AED 5M–10M). A topicals or liquids facility is lower, at AED 10M–50M. A sterile injectable facility requires AED 100M–500M+, and a biologics plant ranges from AED 500M to over AED 2 billion. KIZAD’s pre-installed GMP infrastructure (WFI, HVAC backbone, cleanroom shells) can meaningfully reduce fit-out costs and compress the construction timeline for facilities in the pharmaceutical zone.

What are the benefits of setting up in KIZAD’s pharmaceutical zone?

KIZAD (Khalifa Industrial Zone Abu Dhabi) is UAE’s principal pharmaceutical manufacturing cluster and offers several advantages over mainland or generic free zone alternatives. The zone provides 50-year land leases at AED 30–100 per sqm per year — competitive with industrial land globally for a GMP-compliant zone. Pre-installed GMP infrastructure including WFI water networks, industrial HVAC backbone, and cleanroom shell buildings is available on-site, reducing both upfront capex and construction timeline. KIZAD operators benefit from free zone tax treatment (100% foreign ownership, 0% duty within the zone, and qualifying corporate tax conditions), proximity to Khalifa Port for API imports and GCC pharmaceutical exports, and direct access to the Abu Dhabi Health Cluster’s Mubadala-backed co-investment and government offtake programmes. For manufacturers targeting GCC export markets — a combined market of AED 40B+ — KIZAD’s port adjacency provides a cost-effective distribution gateway to Saudi Arabia, Qatar, and Kuwait, where UAE-manufactured, Halal-certified medicines carry a credibility and compliance advantage.

Can a pharmaceutical manufacturer in the UAE sell to GCC countries?

Yes. UAE-manufactured pharmaceutical products are eligible for export to all GCC member states — Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman. Each GCC country has its own drug registration authority (Saudi FDA, Kuwait KSHHC, Qatar MOPH, etc.) and requires a separate product registration in that country. However, UAE MOH approval and GMP certification carries significant weight in GCC drug registration submissions, as UAE GMP standards align with ICH Q7 and WHO GMP guidelines that most GCC regulators recognise. UAE-origin medicines also carry a Halal-certification advantage in GCC markets, where Halal compliance is increasingly required for hospital formulary inclusion. The GCC pharmaceutical market totals over AED 40 billion, and KIZAD’s location adjacent to Khalifa Port provides cost-competitive maritime and road freight access to all five GCC markets. Manufacturers targeting Saudi Arabia — the largest GCC pharma market — can typically use their UAE MOH Manufacturing Authorization as supporting documentation in their Saudi FDA filing.